Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer

Trial Profile

Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2015

At a glance

  • Drugs Sorafenib (Primary) ; Bicalutamide; Leuprorelin
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Dec 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Sep 2010 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 04 Jun 2010 At least three patients have been enrolled according to information presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top